Injectafer Rejected For First-Line Use; Promising For Second-Line, Panel Says
Executive Summary
Luitpold's Injectafer should be reserved for second-line use for treatment of iron deficiency anemia in postpartum patients and those with heavy uterine bleeding, FDA's Drug Safety and Risk Management Advisory Committee recommended Feb. 1